"Toll-Like Receptor 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that binds DOUBLE-STRANDED RNA. It mediates cellular responses to certain viral pathogens.
| Descriptor ID |
D051196
|
| MeSH Number(s) |
D12.776.543.750.705.910.500.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 3".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 3".
This graph shows the total number of publications written about "Toll-Like Receptor 3" by people in this website by year, and whether "Toll-Like Receptor 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toll-Like Receptor 3" by people in Profiles.
-
YTHDF2 regulates self non-coding RNA metabolism to control inflammation and tumorigenesis. Nat Commun. 2025 Nov 12; 16(1):9946.
-
Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy. ACS Nano. 2025 03 11; 19(9):8852-8866.
-
TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer. Biomaterials. 2022 11; 290:121831.
-
Region-specific innate antiviral responses of the human epididymis. Mol Cell Endocrinol. 2018 09 15; 473:72-78.
-
The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. J Biol Chem. 2016 Jun 03; 291(23):12294-309.
-
Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model. Eur J Immunol. 2016 Mar; 46(3):772-81.
-
TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep. 2015 Dec 03; 5:17622.
-
Idiopathic pulmonary fibrosis: time to get personal? Am J Respir Crit Care Med. 2013 Dec 15; 188(12):1392-4.
-
TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets. 2013 May; 17(5):481-3.
-
The Akt1 isoform is required for optimal IFN-ß transcription through direct phosphorylation of ß-catenin. J Immunol. 2012 Sep 15; 189(6):3104-11.